We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Padmanabhan
Ramnarayan
-
p.ramnarayan@imperial.ac.uk
Mr
Richard
Cleaver
+44 7999 044627
r.cleaver@imperial.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Bronchiolitis
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Nearly 30,000 infants under one are admitted to hospitals in England each year with bronchiolitis, a common viral chest infection. Half of them need oxygen treatment through ‘nasal cannula’ (thin tubes inserted into the nostrils). Most infants respond to nasal cannula oxygen alone, but some need additional breathing support. In these infants, different treatments such as ‘humidified’ (moist) standard oxygen (HSO), high-flow nasal cannula (HFNC) and ‘CPAP’ (pressurised oxygen delivered through the nose) are used. However, it is not clear which of these treatments should be started and when.
HFNC, which provides warm, humidified oxygen at high flow rates, has become a popular breathing support treatment in bronchiolitis, and has mostly replaced the use of HSO in moderately ill infants. HFNC is also used in many hospitals as an alternative to CPAP in severe bronchiolitis. There is little research to show whether HFNC is better than HSO or CPAP. Since HFNC requires specialist equipment, it is more expensive and requires expert nursing resources. There is also concern HFNC may prolong hospital stay.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2025 Protocol article in https://pubmed.ncbi.nlm.nih.gov/40810583/ (added 15/08/2025)
You can take part if:
You may not be able to take part if:
1. Clinical decision that the patient needs immediate intubation and ventilation for life-threatening hypoxia, shock or decreased conscious level.2. Prolonged apnoeas (>10 seconds needing stimulation).3. Ongoing active air leak (pneumothorax, pneumomediastinum).4. Received HSO, HFNC or CPAP for over 2 hours in the previous 24 hours.5. On home ventilation prior to hospital admission.6. Tracheostomy in place.7. Choanal atresia/stenosis, midfacial anomalies or recent craniofacial surgery.8. Previously recruited to the BACHb trial.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Mr
Richard
Cleaver
+44 7999 044627
r.cleaver@imperial.ac.uk
Dr
Padmanabhan
Ramnarayan
-
p.ramnarayan@imperial.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by Imperial College London and funded by NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC).
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 57649
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
